In addition, first promising clinical trials in prostate selleck chemical cancer patients showed that only cancer-specific Tn expression on tumor cell surface enables targeting and site-specific treatment [86]. 2.2. Sialyl-Tn Antigen STn antigen tissue expression and its presence in blood were found in various gynecological cancers originating from the ovary, cervix, endometrium and vulva. The transfer of sialic acid in α2,6-linkage to Tn structure

usually terminates the further elongation of oligosaccharide. Therefore, sialyl-Tn (sTn, Neu5Acα2-6GalNAcα-O-Ser/Thr, Figure 1) expression leads to a shortening of O-glycan chains [2]. STn displays restricted expression in normal tissues Inhibitors,research,lifescience,medical [72,92], but can be detected

at various frequencies in almost all kinds of carcinomas, even more frequently in adenocarcinomas. At least 25-30% of breast cancers are sTn-positive [93] and overexpression of sTn occurs Inhibitors,research,lifescience,medical in almost 40% of breast cancers [94]. STn expression was found to be higher in ovarian cancer patients which were associated with shorter survival [95]. There is increasing evidence that sTn expression is similarly associated Inhibitors,research,lifescience,medical with survival in breast cancer [96,97,98,99], potentially as a short-term outcome [97]. In node-positive breast cancer patients sTn expression was also correlated with a lack of response to adjuvant chemotherapy [98]. Using immunohistochemical staining and anti-sTn monoclonal antibody (TKH-2), the disaccharide was detected in a majority of ovarian and cervical cancers with Inhibitors,research,lifescience,medical no positive match in remaining cancer types, benign, and normal controls [79]. A reduced number of tissue sTn positive samples also showed detectable levels of serum sTn. Using the same mAb directed to sTn, another study found detectable levels of Inhibitors,research,lifescience,medical sTn in serum of ovarian cancer patients which significantly correlated with increased malignancy, metastatic progression and low patient survival [100]. An increased sTn expression in ovarian carcinoma cells was detected when primary tumors were compared with metastatic

lesions [101]. Another study of the same investigators, conducted on tissue samples from 45 patients, confirmed that sTn is widely expressed in ovarian carcinomas and related metastases, but could not verify sTn expression to be predictable of disease outcome [102]. There Resminostat is a clear indication that sTn expression in tissue and blood serum correlates with tumor progression in breast and ovarian cancer. The mechanisms, underlying the appearance of this O-glycan in several types of carcinomas is still unknown, as is its varied tissue expression. One possible explanation suggests an increased gene expression of ST6GalNAc-I glycosyltransferase, the enzyme which transfers sialic acid to Tn antigen, thus creating Neu5Acα2-6GalNAc, which is the sTn epitope [103].